Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2006

View Archived Issues

Ipsen presents novel farnesyltransferase inhibitors

Viropharam present a novel, selective and potent anti-HCV candidate

Amgen reports on new potent class of KDR inhibitors

Pfizer profiles its novel lead 5-HT/NA reuptake inhibitor

GSK presents two novel and selective COX-2 inhibitors

Wex cleared to continue Canadian development of Tectin for cancer-related pain

CardioVascular BioTherapeutics signs CRO for phase II cardiovascular trial

King to acquire rights to Avinza

ACE BioSciences and U.S. Navy team up on travelers' diarrhea vaccine

Advisory committee recommends study to support new Abraxane indication

Supprelin-LA NDA accepted for review

Trimeris and Roche extend HIV fusion inhibitors research agreement

New phase III study evaluates Xyrem for fibromyalgia syndrome

Eisai to acquire Ligand's oncology products

Medivir licenses MIV-606 to Epiphany Biosciences

Shareholders approve separation of Akzo Nobel companies

European orphan drug designation for VAS-203 in traumatic brain injury

Merck begins phase I for estrogen receptor compound from Karo Bio collaboration

GenoMed's sickle cell treatment approach shows promise

Promising clinical activity of Advexin deserves further evaluation

AEterna Zentaris makes great strides in Q2

Axcan presents third quarter review

Genentech receives complete response letter for Avastin in metastatic breast cancer

Cortex submits complete response to lift clinical hold on CX-717

Ranbaxy launches Avessa for asthma in India

Novel orally active CCR1 antagonist for inflammatory disorders from Berlex

New water-soluble cannabinoid CB1 receptor agonists described by Organon

Recent patents impart new oncolytic drugs

Recent Schering-Plough patents report novel chemokine CCR5 antagonists for HIV

Novel mGluR5 receptor antagonists emerge from Novartis R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...